Letters, Statements and Analysis - 2014

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.

 

2017

 

2016

 

2015

 

2014

 

2013

 

 

December

12/22/2014

AMCP signs joint letter to FDA Oncologic Drugs Advisory Committee in support of the effort to approve biosimilar drugs under the BPCIA pathway. 

12/19/2014

AMCP comments to HHS on proposed rule for essential health benefits in federal marketplaces for 2016-17 

12/5/2014

AMCP sends comments to the U.S. House Ways & Means Committee regarding proposed anti-fraud provisions in the Protecting the Integrity of Medicare Act of 2014 (PIMA) 

 

November

11/18/2014

AMCP opposes Ohio SB 364 restricting drug tiers and pricing 

11/3/2014

AMCP submits comments to CMS Innovation Center Request for Comments on Testing New MTM Models and Other Innovative Health Delivery Strategies for Medicare and Medicaid 

 

October

10/21/2014

AMCP supports Idaho Board of Pharmacy proposed rule to allow automatic substitution of interchangeable biosimilars 

10/6/2014

AMCP comments on FDA draft guidance for industry on reference product exclusivity for biological products filed under Section 351(a) of the Public Health Service Act. 

10/2/2014

AMCP supports NY AB 7521 addressing collaborative drug therapy management 

AMCP supports NY SB 5400 addressing collaborative drug therapy management 

 

September

9/25/2014

California Governor vetoes AB 2418 legislation opposed by AMCP mandating medication synchronization programs 

9/18/2014

AMCP submits comments to South Carolina Board of Pharmacy supporting vaccination statute modifications 

9/17/2014

AMCP submits comments to World Health Organization over concerns with biologic qualifier proposal 

9/2/2014

AMCP sends recommendations to CMMI to improve MTM and implement administrative efficiencies in Medicare Part D 

 

August

8/28/2014

AMCP comments to the House Ways & Means Committee on draft legislation addressing controlled substances in Medicare Part D. 

8/20/2014

AMCP joins three other national pharmacy organizations urging CMS to exempt CME activities from open payments reporting and to consider ACPE approved programs as exempt 

8/13/2014

AMCP Remarks: Bipartisan HELP Prescription Drug Abuse Working Group 

8/11/2014

AMCP submits comments on FDA Draft Guidance for Industry on Pharmacology Data to Support Biosimilarity 

AMCP opposes IL HB 6277 addressing specialty tiers 

8/6/2014

AMCP President-Elect, Raulo Frear, testifies before Idaho Board of Pharmacy regarding proposed biosimilar regulations 

 

July

7/30/2014

AMCP opposes CA AB 2418 addressing mail order and med synchronization 

7/29/2014

AMCP comments to PQA on Draft Performance and Quality Measures 

7/28/2014

AMCP submits comments to Idaho Board of Pharmacy regarding proposed biosimilar definition 

7/8/2014

AMCP discourages Council of State Governments from recommending template biosimilar legislation in the states 

7/1/2014

AMCP comments to CMS on Medicare proposed 2015 hospice payment policy for medication coverage 

AMCP joins more than 30 groups urging FDA to consider uniform biosimilar names 

 

June

6/30/2014

AMCP supports NASPER legislation in the U.S. Senate 

6/27/2014

AMCP requests modifications to SB 7369 addressing uniform prior authorization 

AMCP requests modifications to AB 9765 addressing uniform prior authorization 

6/25/2014

AMCP opposes Ohio SB 258 addressing pharmacy audits 

6/11/2014

AMCP asks Governor Kasich of Ohio to veto SB 99 addressing coverage for orally administered chemotherapy drugs 

 

May

5/22/2014

AMCP opposes Puerto Rico HB 1952 addressing biosimilars 

5/20/2014

AMCP asks Governor Markell of Delaware to veto SB 118 addressing biosimilars 

5/19/2014

AMCP opposes expansion of MTM in U.S. HR 1024 

5/16/2014

AMCP seeks modification of MN HF 2402 addressing MAC pricing and electronic prior authorization 

5/5/2014

AMCP seeks modification of IL HB 3638 addressing uniform prior authorization 

5/2/2014

AMCP opposes Louisiana SB 165 addressing specialty tiers 

5/1/2014

AMCP opposes Florida SB 1354 addressing step therapy 

AMCP nominates member Michael Tocco for FDA Pharmacy Compounding Advisory Committee 

 

April

4/30/2014

AMCP comments on U.S. House Ways & Means Committee hearing supporting approaches to curb Medicare fraud 

4/29/2014

AMCP opposes Florida HB 1001 addressing step therapy 

4/28/2014

AMCP supports letter to DEA opposing hydrocodone rescheduling 

4/23/2014

AMCP opposes Delaware SB 118 addressing biological products 

4/22/2014

AMCP comments on Exchange Marketplace Standards for 2015 and Beyond Proposal urge CMS not to adopt mandatory exceptions process 

4/18/2014

AMCP opposes Minnesota HF 2402 addressing e-prior authorization 

AMCP opposes Minnesota SF 2087 addressing e-prior authorization 

4/16/2014

AMCP opposes Missouri HB 2152 addressing MAC pricing 

4/9/2014

AMCP Opposes Connecticut SB 394 addressing step therapy and mail order 

 

March

3/28/2014

AMCP Opposes Wisconsin AB 392 addressing coverage for orally administered chemotherapy drugs 

3/24/2014

AMCP Opposes Maine LD 1624 addressing MAC Pricing 

3/18/2014

AMCP Opposes Connecticut SB 191 addressing coverage for orally administered chemotherapy drugs 

AMCP Opposes Connecticut Raised Bill 5251 addressing cost sharing limitations 

3/14/2014

AMCP Opposes Kansas HB 2688 addressing multiple restrictions on PBMs 

AMCP Opposes Florida SB 1014 addressing MAC pricing 

AMCP Opposes Florida HB 765 addressing MAC pricing 

AMCP Comments on PQA Draft Measures 

3/11/2014

AMCP asks Missouri Governor Nixon to veto SB 668 addressing coverage for orally administered chemotherapy drugs 

AMCP asks the U.S. House of Representatives to support HR 4160, asking CMS to prohibit further action on the Medicare Part D proposed rule 

3/7/2014

AMCP comments on Medicare Part D Proposed Rule 

AMCP comments on 2015 Draft Medicare Part D Call Letter 

3/6/2014

AMCP asks Indiana Governor Pence to veto SB 262 addressing biosimilars 

AMCP opposes Maryland SB 952 addressing MAC pricing 

AMCP opposes Maryland HB 793 addressing MAC pricing 

3/5/2014

AMCP supports efforts to ensure safety in generic drug labeling by asking FDA to change proposed rule 

AMCP opposes Maryland SB 825 addressing Specialty Tiers 

AMCP opposes Maryland HB 875 addressing Specialty Tiers 

AMCP opposes Maryland SB 874 addressing Specialty Drugs 

AMCP opposes Maryland HB 761 addressing Specialty Drugs 

 

February

2/28/2014

AMCP responds to Federal Trade Commission's questions concerning the impact of state biosimilar legislation on competition 

AMCP submits comments in response to CMMI RFI on Part D integration into ACOs 

Senate Finance Committee urges CMS to rescind Medicare Part D proposed rule 

2/27/2014

AMCP Opposes Maryland SB 641 addressing coverage for orally administered chemotherapy drugs 

AMCP Opposes Maryland HB 625 addressing coverage for orally administered chemotherapy drugs 

AMCP Opposes Maryland SB 622 addressing step therapy 

AMCP Opposes Maryland HB 1233 addressing step therapy 

2/26/2014

AMCP signs joint letter of opposition to Pennsylvania Senate Appropriations Committee re: SB 405 addressing biosimilars 

2/24/2014

AMCP Opposes Ohio SB 99 addressing coverage for orally administered chemotherapy drugs 

2/21/2014

AMCP Comments to CMS on Issuers Letter with Concerns on Mandatory Transition Supplies 

2/20/2014

AMCP Supports Georgia SB 370 addressing Biosimilars 

2/19/2014

AMCP Opposes Arizona SB 1361 addressing electronic prior authorization 

2/18/2014

AMCP signs joint letter asking CMS to withdraw the Medicare Part D Proposed Rule 

2/13/2014

AMCP Opposes Alaska SB 8 addressing Pharmacy Audits 

AMCP Opposes Florida HB 745 Addressing Pharmacy Audits 

AMCP Opposes Florida SB 702 Addressing Pharmacy Audits 

AMCP Opposes Indiana SB 262 addressing Biosimilars 

2/12/2014

AMCP Opposes Arizona SB 1247 addressing Oral Chemo Parity 

AMCP Supports Virginia Board of Pharmacy Petition to Prohibit Point of Sale Coupons in Pharmacy 

AMCP Opposes Wisconsin SB 300 addressing Oral Chemo Parity 

2/11/2014

AMCP Summary of Focus Areas for Medicare Part D Proposed Rule Comments 

AMCP Perspective on Comments for Medicare Part D Proposed Rule Comments 

2/3/2014

AMCP Opposes Washington HB 2326 addressing Biosimilars 

AMCP Opposes Washington SB 6091 addressing Biosimilars 

AMCP Submits Comments in Response to FDA Draft Guidance Documents on Compounding (503A) 

AMCP Submits Comments in Response to FDA Draft Guidance Documents on Compounding (503B) 

2/2/2014

AMCP Letter Concerning FDA prioritization in Consolidated Appropriations Act of 2014 

 

January

1/31/2014

AMCP Opposes Virginia HB 304 addressing Specialty Tiers 

AMCP Opposes Ohio SB 258 addressing Pharmacy Audits 

1/29/2014

AMCP Thanks Congressional Appropriations Leadership for their Funding Support of the FDA 

AMCP Opposes Mississippi HB 1268 addressing Biosimilars 

1/28/2014

AMCP Opposes Hawaii SB 2173 addressing Specialty Tiers 

AMCP Opposes Mississippi SB 2731 Addressing Biosimilars 

AMCP Opposes Virginia HB 108 addressing Pharmacy Audits 

1/24/2014

AMCP Submits Comments to CMS on Quality Measures in the Health Insurance Exchanges 

AMCP Opposes Indiana SB 262 addressing Biosimilar Substitution 

1/13/2014

AMCP Comments in Response to CMS' December 2013 Guidance on Coverage and Payment for Hospice Medication Coverage 

1/9/2014

AMCP Opposes Massachusetts SB 439 addressing Step Therapy 

1/7/2014

AMCP Comments on the AHRQ Draft Systemic Review: Medication Therapy Management 

Content for class "break" Goes Here